🧪
hypothesis

Iron Chelation Therapy Targeting the Labile Iron Pool

Hypothesis

Iron Chelation Therapy Targeting the Labile Iron Pool

Lipophilic iron chelators (deferasirox, VK28 analogs) cross the BBB to sequester labile iron, preventing Fenton chemistry and subsequent lipid peroxidation in astrocytes.
🧬 Labile iron pool (LIP) / Fenton chemistry🩺 neurodegeneration🎯 Composite 64%💱 $0.56▼11.7%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 3 oppose
✓ All Quality Gates Passed
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite64%

🧪 Overview

Lipophilic iron chelators (deferasirox, VK28 analogs) cross the BBB to sequester labile iron, preventing Fenton chemistry and subsequent lipid peroxidation in astrocytes. This preserves AQP4 perivascular localization and water homeostasis. Mechanistically plausible given iron-dependent ferroptosis, but prior clinical trials of deferoxamine in TBI and stroke showed limited efficacy, raising concerns about relevance to human acute CNS injury. Requires rigorous dose-response with MRI-based iron quantification and brain drug levels.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["CSF Arterial Inflow<br/>Periarterial Space"]
    B["AQP4 on Astrocyte Endfeet<br/>Perivascular Polarization"]
    C["Glymphatic Flow<br/>ISF Convective Clearance"]
    D["Abeta/Tau Efflux<br/>Perivenous Drainage"]
    E["Lymphatic Outflow<br/>Cervical Lymph Nodes"]
    F["AQP4 Mislocalization<br/>in AD/Aging"]
    G["Reduced ISF Clearance<br/>Aggregate Accumulation"]
    A --> B
    B --> C
    C --> D
    D --> E
    F -.->|"impairs"| C
    F --> G
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#1b5e20,stroke:#81c784,color:#81c784
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
Iron-dependent ferroptosis mechanism established
PMID:32109384
Supports
Iron chelation prevents AQP4 dysregulation in edema models
PMID:35633334
Supports
Ferritinophagy releases iron to promote ferroptosis in neurodegeneration
PMID:34163052
Contradicts
Deferoxamine failed in TBI clinical trials; no functional improvement
PMID:N/A
Contradicts
Deferasirox designed for chronic iron overload, poor fit for acute CNS rescue
PMID:N/A
Contradicts
Deferoxamine is a poor BBB penetrant
PMID:N/A
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — LABILE

No curated PDB or AlphaFold mapping for LABILE yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for Labile iron pool (LIP) →

No DepMap CRISPR Chronos data found for Labile iron pool (LIP).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.4%
Volatility
Low
0.0031
Events (7d)
2
Price History
▼11.7%

💾 Resource Usage

LLM Tokens
12,340
$0.0370
Total Cost
$0.0370

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF patients with acute ischemic stroke (NIHSS 6-15) receive deferasirox (20 mg/kg/day IV for 5 days starting within 6 hours of symptom onset) THEN brain R2* relaxometry in the ischemic territory will R2* reduction ≥25% indicating decreased brain iron in the lesioned hemisphere— no observation —pending0.45
IF C57BL/6 mice receive VK28 analog (10 mg/kg IP daily for 14 days) starting 1 hour after middle cerebral artery occlusion (MCAO), THEN quantitative immunofluorescence of AQP4 perivascular coverage wiAQP4 perivascular localization restored to ≥70% of sham control; blood-brain barrier permeability reduced by ≥40%— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF C57BL/6 mice receive VK28 analog (10 mg/kg IP daily for 14 days) starting 1 hour after middle cerebral artery occlusion (MCAO), THEN quantitative immunofluorescence of AQP4 perivascular coverage will increase to ≥70% of sham levels, and Evans blue extravasation will decrease by ≥40% at day 14 pos
Predicted outcome: AQP4 perivascular localization restored to ≥70% of sham control; blood-brain barrier permeability reduced by ≥40%
Falsification: AQP4 perivascular coverage remains <60% of sham levels, or Evans blue extravasation shows no significant reduction compared to vehicle-treated MCAO mice
pendingconf 45%
IF patients with acute ischemic stroke (NIHSS 6-15) receive deferasirox (20 mg/kg/day IV for 5 days starting within 6 hours of symptom onset) THEN brain R2* relaxometry in the ischemic territory will decrease by ≥25% compared to placebo at day 7, as quantified by 3T MRI.
Predicted outcome: R2* reduction ≥25% indicating decreased brain iron in the lesioned hemisphere
Falsification: No statistically significant difference in R2* between treatment and placebo groups (p > 0.05), or R2* increases rather than decreases in the treatment arm
View on SciDEX ↗